RecruitingNot ApplicableNCT05375643

SURGE: Supporting Utility and Representation in Genomics-based Cancer Trial Enrollment (Intervention)


Sponsor

Nadine Jackson, MD, MPH

Enrollment

210 participants

Start Date

Apr 3, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

SURGE aims to increase representation in clinical trial enrollment by addressing barriers to genomic testing, which is increasingly needed to assess precision clinical trial eligibility and access standard precision therapies. The study is an interventional pilot meant primarily to assess the feasibility of the intervention. The intervention is comprised of a patient navigator, text message questionnaire, and informational video.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a behavioral approach called SURGE for people with gastrointestinal cancer, hematologic cancer, and other related conditions. The study is currently recruiting participants at 3 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BEHAVIORALSURGE

Video with or without person to person guidance to support decision making around genetic testing


Locations(3)

Dana Farber Cancer Institute

Boston, Massachusetts, United States

Dana-Farber Cancer Institute at St. Elizabeth's Medical Center

Brighton, Massachusetts, United States

Dana-Farber Cancer Instiute - Merrimack Valley

Methuen, Massachusetts, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05375643


Related Trials